|
1
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ; Panel members. Strategies for
subtypes - dealing with the diversity of breast cancer: highlights
of the St Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chambon P, Weill JD and Mandel P:
Nicotinamide mononucleotide activation of new DNA-dependent
polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res
Commun. 11:39–43. 1963. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kiliańska ZM, Żołnierczyk J and
Węsierska-Gądek J: Biological activity of poly(ADP-ribose)
polymerase-1. Postepy Hig Med Dosw. 64:344–363. 2010.(In
Polish).
|
|
4
|
Shieh WM, Ame JC, Wilson MV, Wang ZQ, Koh
DW, Jacobson MK and Jacobson EL: Poly(ADP-ribose) polymerase null
mouse cells synthesize ADP-ribose polymers. J Biol Chem.
273:30069–30072. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Otto H, Reche PA, Bazan F, Dittmar K, Haag
F and Koch-Nolte F: In silico characterization of the family
of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics.
6:1392005. View Article : Google Scholar
|
|
6
|
Krishnakumar R and Kraus WL: The PARP side
of the nucleus: molecular actions, physiological outcomes, and
clinical targets. Mol Cell. 39:8–24. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mangerich A and Bürkle A: How to kill
tumor cells with inhibitors of poly(ADP-ribosyl)ation. Int J
Cancer. 128:251–265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Langelier MF, Servent KM, Rogers EE and
Pascal JM: A third zinc-binding domain of human poly(ADP-ribose)
polymerase-1 coordinates DNA-dependent enzyme activation. J Biol
Chem. 283:4105–4114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Langelier MF, Ruhl DD, Planck JL, Kraus WL
and Pascal JM: The Zn3 domain of human poly(ADP-ribose)
polymerase-1 (PARP-1) functions in both DNA-dependent
poly(ADP-ribose) synthesis activity and chromatin compaction. J
Biol Chem. 285:18877–18887. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu JF and Silver DP: Poly ADP-ribose
polymerase inhibitors: science and current clinical development.
Curr Opin Oncol. 22:567–572. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lord CJ and Ashworth A: The DNA damage
response and cancer therapy. Nature. 481:287–294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Javle M and Curtin NJ: The role of PARP in
DNA repair and its therapeutic exploitation. Br J Cancer.
105:1114–1122. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Horton JK and Wilson SH: Hypersensitivity
phenotypes associated with genetic and synthetic inhibitor-induced
base excision repair deficiency. DNA Repair. 6:530–543. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ame JC, Spenlehauer C and de Murcia G: The
PARP superfamily. Bioessays. 26:882–893. 2004. View Article : Google Scholar
|
|
15
|
Plummer ER and Calvert H: Targeting
poly(ADP-ribose) polymerase: a two-armed strategy for cancer
therapy. Clin Cancer Res. 13:6252–6256. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Woodhouse BC and Dianov GL: Poly
ADP-ribose polymerase-1: an international molecule of mystery. DNA
Repair. 7:1077–1086. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dębska S, Kubicka J, Czyżkowski R, Habib M
and Potemski P: PARP inhibitors - theoretical basis and clinical
application. Postepy Hig Med Dosw. 66:311–321. 2012.(In
Polish).
|
|
18
|
Sobin LH and Wittekind C: TNM
classification of malignant tumours. 5th edition. Wiley-Liss Inc;
New York: 2002
|
|
19
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar
|
|
20
|
Halon A, Materna V, Drag-Zalesinka M,
Nowak-Markwitz E, Gansukh T, Donizy P, Spaczynski M, Zabel M,
Dietel M, Lage H and Surowiak P: Estrogen receptor alpha expression
in ovarian cancer predicts longer overall survival. Pathol Oncol
Res. 17:511–518. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Halon A, Nowak-Markwitz E, Maciejczyk A,
Pudelko M, Gansukh T, Györffy B, Donizy P, Murawa D, Matkowski R,
Spaczynski M, Lage H and Surowiak P: Loss of estrogen receptor beta
expression correlates with shorter overall survival and lack of
clinical response to chemotherapy in ovarian cancer patients.
Anticancer Res. 31:711–718. 2011.
|
|
22
|
Szczuraszek K, Halon A, Materna V, Mazur
G, Wrobel T, Kuliczkowski K, et al: Elevated YB-1 expression is a
new unfavorable prognostic factor in non-Hodgkin’s lymphomas.
Anticancer Res. 31:2963–2970. 2011.PubMed/NCBI
|
|
23
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German).
|
|
24
|
Lage H and Dietel M: Multiple mechanisms
confer different drug-resistant phenotypes in pancreatic carcinoma
cells. J Cancer Res Clin Oncol. 128:349–357. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Osheroff N, Corbert AH and Robinson MJ:
Mechanism of action of topoisomerase II-targeted antineoplastic
drugs. Adv Pharmacol. 29B:105–126. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wichert A, Stege A, Midorikawa Y, Holm PS
and Lage H: Glypican-3 is involved in cellular protection against
mitoxantrone in gastric carcinoma cells. Oncogene. 23:945–955.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kellner U, Hutchinson L, Seidel A, Lage H,
Danks MK, Dietel M and Kaufmann SH: Decreased drug accumulation in
a mitoxantrone-resistant gastric carcinoma cell line in the absence
of P-glycoprotein. Int J Cancer. 71:817–824. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lage H, Perlitz C, Abele R, Tampe R,
Dietel M, Schadendorf D and Sinha P: Enhanced expression of human
ABC-transporter tap is associated with cellular resistance to
mitoxantrone. FEBS Lett. 503:179–184. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lage H: Molecular analysis of therapy
resistance in gastric cancer. Dig Dis. 21:326–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Györffy B, Surowiak P, Kiesslich O,
Denkert C, Schäfer R, Dietel M and Lage H: Resistance prediction
profile for eleven anticancer agents at clinical concentrations
based on the gene expression pattern of thirty cell lines. Int J
Cancer. 118:1699–1712. 2006.
|
|
31
|
Altan N, Chen Y, Schindler M and Simon SM:
Defective acidification in human breast tumor cells and
implications for chemotherapy. J Exp Med. 187:1583–1598. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vickers PJ, Dickson RB, Shoemaker R and
Cowan KH: A multidrug-resistant MCF-7 human breast cancer cell line
which exhibits cross-resistance to antiestrogens and
hormone-independent tumor growth in vivo. Mol Endocrinol.
2:886–892. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ke W, Yu P, Wang J, Wang R, Guo C, Zhou L,
Li C and Li K: MCF-7/ADR cells (re-designated NCI/ADR-RES) are not
derived from MCF-7 breast cancer cells: a loss for breast cancer
multidrug-resistant research. Med Oncol (Suppl). 1:S135–S141. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Domagala P, Huzarski T, Lubinski J, Gugala
K and Domagala W: PARP-1 expression in breast cancer including
BRCA1-associated, triple negative and basal-like tumors: possible
implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat.
127:861–869. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
von Minckwitz G, Müller BM, Loibl S,
Budczies J, Hanusch C, Darb-Esfahani S, et al: Cytoplasmic
poly(adenosine diphosphate-ribose) polymerase expression is
predictive and prognostic in patients with breast cancer treated
with neoadjuvant chemotherapy. J Clin Oncol. 29:2150–2157.
2011.
|
|
36
|
Rojo F, Garcia-Parra J, Zazo S, Tusquets
I, Ferrer-Lozano J, Menendez S, et al: Nuclear PARP-1 protein
overexpression is associated with poor overall survival in early
breast cancer. Ann Oncol. 23:1156–1164. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ozretic L, Rhiem K, Huss S, Wappenschmidt
B, Markiefka B, Sinn P, Schmutzler RK and Buettner R: High nuclear
poly(adenosine diphosphate-ribose) polymerase expression is
predictive for BRCA1- and BRCA2-deficient breast cancer. J Clin
Oncol. 29:4586–4588. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Surowiak P, Materna V, Matkowski R,
Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, et al: Relationship
between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein
in invasive breast cancers and their prognostic significance.
Breast Cancer Res. 7:R862–R870. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Surowiak P, Materna V, Györffy B,
Matkowski R, Wojnar A, Maciejczyk A, et al: Multivariate analysis
of oestrogen receptor alpha, pS2, metallothionein and CD24
expression in invasive breast cancers. Br J Cancer. 95:339–346.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maciejczyk A, Szelachowska J, Ekiert M,
Matkowski R, Hałoń A, Lage H and Surowiak P: Elevated nuclear YB1
expression is associated with poor survival of patients with early
breast cancer. Anticancer Res. 32:3177–3184. 2012.PubMed/NCBI
|
